Trial Profile
Molecular Imaging of Zirconium-89-labeled Atezolizumab as a Tool to Investigate Atezolizumab Biodistribution in High-risk Diffuse Large B-cell Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Diagnostic use; Pharmacokinetics
- Acronyms PDL1 imaging in DLBCL
- 11 May 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 14 Jun 2019 Status changed from not yet recruiting to recruiting.
- 12 Oct 2018 New trial record